.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Chubb
AstraZeneca
Teva
Boehringer Ingelheim
Novartis
Julphar
Cantor Fitzgerald
Queensland Health
Dow

Generated: November 19, 2017

DrugPatentWatch Database Preview

Bayer Healthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAYER HEALTHCARE, and when can generic versions of BAYER HEALTHCARE drugs launch?

BAYER HEALTHCARE has twenty-eight approved drugs.

There are ten US patents protecting BAYER HEALTHCARE drugs.

There are two hundred and twenty-three patent family members on BAYER HEALTHCARE drugs in fifty-three countries and six supplementary protection certificates in three countries.

Summary for Bayer Healthcare

International Patents:223
US Patents:10
Tradenames:22
Ingredients:12
NDAs:28
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc
CLARITIN
loratadine
TABLET;ORAL019658-002Nov 27, 2002OTCYesYes► Subscribe► Subscribe► Subscribe
Bayer Healthcare Llc
MYCELEX-7
clotrimazole
CREAM;VAGINAL018230-002Dec 26, 1991OTCNoNo► Subscribe► Subscribe► Subscribe
Bayer Healthcare
ALIQOPA
copanlisib dihydrochloride
POWDER;IV (INFUSION)209936-001Sep 14, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Healthcare Llc
SHADE UVAGUARD
avobenzone; octinoxate; oxybenzone
LOTION;TOPICAL020045-001Dec 7, 1992DISCNYesNo► Subscribe► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN-D 24 HOUR
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL020470-002Nov 27, 2002OTCYesYes► Subscribe► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN
loratadine
CAPSULE;ORAL021952-001Jun 16, 2008OTCYesYes► Subscribe► Subscribe► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
FOR SUSPENSION;ORAL022283-001Jun 17, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Healthcare Llc
CLARITIN HIVES RELIEF
loratadine
SYRUP;ORAL020641-003Nov 19, 2003DISCNYesNo► Subscribe► Subscribe► Subscribe
Bayer Healthcare
ALIQOPA
copanlisib dihydrochloride
POWDER;IV (INFUSION)209936-001Sep 14, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc
CLARITIN
loratadine
TABLET;ORAL019658-002Nov 27, 2002► Subscribe► Subscribe
Bayer Healthcare Llc
MYCELEX
clotrimazole
CREAM;TOPICAL018183-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Bayer Healthcare Llc
MYCELEX
clotrimazole
CREAM;TOPICAL018183-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN REDITABS
loratadine
TABLET, ORALLY DISINTEGRATING;ORAL020704-002Nov 27, 2002► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN
loratadine
SYRUP;ORAL020641-002Nov 27, 2002► Subscribe► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009► Subscribe► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
FOR SUSPENSION;ORAL022283-001Jun 17, 2013► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN-D
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL019670-002Nov 27, 2002► Subscribe► Subscribe
Bayer Healthcare Llc
CLARITIN-D 24 HOUR
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL020470-002Nov 27, 2002► Subscribe► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAYER HEALTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
omeprazole and sodium bicarbonate
Capsules20 mg/1100 mg
ZEGERID OTC
4/20/2010

Non-Orange Book Patents for Bayer Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE45198Omeprazole solution and method for using same► Subscribe
6,939,550 Stabilized antihistamine syrup► Subscribe
6,514,520 Stabilized antihistamine syrup► Subscribe
8,129,386Fused azole-pyrimidine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bayer Healthcare Drugs

Country Document Number Estimated Expiration
South Korea20040047771► Subscribe
Slovenia1549652► Subscribe
Uruguay30761► Subscribe
Japan2002516860► Subscribe
MexicoPA05001808► Subscribe
Norway20052076► Subscribe
European Patent Office1082117► Subscribe
South Korea20090096440► Subscribe
Canada2594185► Subscribe
Taiwan200413379► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bayer Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
01C/013Belgium► SubscribePRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB11/013United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB01/012United Kingdom► SubscribePRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Chubb
Argus Health
McKinsey
Dow
Covington
Cantor Fitzgerald
Fuji
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot